AstraZeneca Launches Genomics Initiatives with HLI, Sanger, and FIMM

Human Longevity Inc. (HLI) will sequence and analyze up to 500,000 DNA samples from patients in AstraZeneca clinical trials over 10 years in one of four genomics-focused initiatives announced today by the pharma giant and its global biologics R&D arm MedImmune. The value of the collaboration with HLI and other initiatives was not disclosed. AstraZeneca has agreed to share with HLI up to 500,000 DNA samples collected under optional informed consent in the pharma giant’s clinical studies. HLI plans to sequence the genomes from these samples, as well as from future samples donated over the next decade by patients in AstraZeneca trials. AstraZeneca will join HLI in interpreting the genomic data using HLI’s machine learning, pattern recognition, and analytical techniques. HLI said genomic insights collected from the samples will be…


Link to Full Article: AstraZeneca Launches Genomics Initiatives with HLI, Sanger, and FIMM